Long-term outcome of patients with vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis

We present the long-term outcomes of 44 patients who developed cerebral venous sinus thrombosis after vaccination with the adenoviral vector ChAdOx1 nCoV-19 COVID-19 vaccine. Assessment of the Extended Glasgow Outcome Scale was performed within 3–6 months after the initial hospital admissions. Patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Kehr, Sarah, Berg, Philipp, Müller, Susanne, Fiedler, Sarah A., Meyer, Britta, Ruppert-Seipp, Gabriele, Witzenhausen, Cornelia, Wolf, Marc E., Henkes, Hans H., Oberle, Doris, Keller-Stanislawski, Brigitte, Funk, Markus B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255460/
https://www.ncbi.nlm.nih.gov/pubmed/35790739
http://dx.doi.org/10.1038/s41541-022-00491-z
Descripción
Sumario:We present the long-term outcomes of 44 patients who developed cerebral venous sinus thrombosis after vaccination with the adenoviral vector ChAdOx1 nCoV-19 COVID-19 vaccine. Assessment of the Extended Glasgow Outcome Scale was performed within 3–6 months after the initial hospital admissions. Patient outcomes ranged from good recovery (13 patients, 29.6%) to moderate disability (11 patients, 25.0%) and severe disability or vegetative state (6 patients, 13.6%). Fatal outcomes were reported in 14 patients (31.8%).

Ejemplares similares